We’re encouraged to share that Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) / Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) is now officially listed in Aetna’s medical policy—an important milestone for recognition and access to care.
Why Aetna’s Recognition of PANS/PANDAS Matters
- The policy recognizes that symptom onset typically occurs between ages 3 and puberty
- This inclusion may signal progress, and we anticipate more insurers may follow suit
- Clear diagnostic and documentation criteria are outlined for medical necessity
What Aetna’s PANS/PANDAS Medial Policy Includes
Therapy may be considered medically necessary when the following criteria are met:
Diagnostic Criteria
The child meets PANS Research Consortium diagnostic criteria, including:
- A sudden, dramatic onset (less than one month) of obsessive compulsive disorder (OCD) or severely restricted food intake
- At least two additional neuropsychiatric symptoms with acute onset, such as:
- Anxiety
- Emotional lability and/or depression
- Irritability, aggression, or severe oppositional behaviors
- Developmental or behavioral regression
- Decline in school performance (including ADHD like symptoms, memory, or cognitive changes)
- Sensory or motor abnormalities
- Physical symptoms such as sleep disturbances, bedwetting, or urinary frequency
Additional Requirements for Medical Necessity
- Symptom onset between 3 years of age and puberty
- Other potential causes of symptoms have been ruled out
- The child has tried and not responded to systemic corticosteroids
- Submission of a baseline objective symptom assessment, such as:
- Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
- Clinical Global Impression of Severity (CGIS)
- Parent-Rated PANS Scale
Continuation of Therapy Criteria
Ongoing treatment may be considered medically necessary when there is documented objective clinical improvement, measured using the same standardized assessment tools.
A Step Toward Access to PANS/PANDAS Care
This is a meaningful step toward greater awareness, validation, and access to care for children and families affected by PANS/PANDAS. We’ll continue watching for updates as insurance coverage evolves.
For full policy details, Visit Aetna’s medical policy page: https://www.aetna.com/cpb/medical/data/200_299/0206.html